Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Other hematologic neoplasm 8Dermatologic 7Gastrointestinal 6Thoracic 5Genitourinary 3Plasma cell 2Other solid neoplasm 2Breast 2Tumor-Agnostic 1Sarcoma 1Myeloid 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1

Interventions

Cisplatin 145pembrolizumab 129Carboplatin 125Injections 108Pemetrexed 97Paclitaxel 97Gemcitabine 85Irinotecan 75Nivolumab 71Cyclophosphamide 71Docetaxel 68Bevacizumab 57Oxaliplatin 49Fluorouracil 48atezolizumab 46Capecitabine 46Etoposide 42Leucovorin 41tislelizumab 40toripalimab 36fludarabine 32Ipilimumab 30Drug Therapy 30Topotecan 29durvalumab 28Vincristine 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26Specimen Handling 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × oblimersen × Other solid neoplasm × Clear all
NCT00054548 2013-05-16

Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
55 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00636545 2012-04-06

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Genta Incorporated

Phase 1 Completed
25 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡